

Transgenic isolation of skeletal muscle and kidney defects in laminin $\beta 2$ mutant mice: implications for Pierson syndrome

Jeffrey H. Miner^{1,2,*}, Gloriosa Go¹, Jeanette Cunningham¹, Bruce L. Patton³ and George Jarad¹

Pierson syndrome is a recently defined disease usually lethal within the first postnatal months and caused by mutations in the gene encoding laminin $\beta 2$ (*LAMB2*). The hallmarks of Pierson syndrome are congenital nephrotic syndrome accompanied by ocular abnormalities, including microcoria (small pupils), with muscular and neurological developmental defects also present. *Lamb2*^{-/-} mice are a model for Pierson syndrome; they exhibit defects in the kidney glomerular barrier, in the development and organization of the neuromuscular junction, and in the retina. *Lamb2*^{-/-} mice fail to thrive and die very small at 3 weeks of age, but to what extent the kidney and neuromuscular defects each contribute to this severe phenotype has been obscure, though highly relevant to understanding Pierson syndrome. To investigate this, we generated transgenic mouse lines expressing rat laminin $\beta 2$ either in muscle or in glomerular epithelial cells (podocytes) and crossed them onto the *Lamb2*^{-/-} background. Rat $\beta 2$ was confined in skeletal muscle to synapses and myotendinous junctions, and in kidney to the glomerular basement membrane. In transgenic *Lamb2*^{-/-} mice, $\beta 2$ deposition in only glomeruli prevented proteinuria but did not ameliorate the severe phenotype. By contrast, $\beta 2$ expression in only muscle restored synaptic architecture and led to greatly improved health, but the mice died from kidney disease at 1 month. Rescue of both glomeruli and synapses was associated with normal weight gain, fertility and lifespan. We conclude that muscle defects in *Lamb2*^{-/-} mice are responsible for the severe failure to thrive phenotype, and that renal replacement therapy alone will be an inadequate treatment for Pierson syndrome.

KEY WORDS: Pierson syndrome, Human, *LAMB2*, Mouse, Rat

INTRODUCTION

Basement membranes (BMs) are thin sheets of specialized extracellular matrix that underlie all epithelial and endothelial cells, surround all muscle fibers, fat cells and Schwann cell/axon units in peripheral nerves, and encase the entire central nervous system. BMs have been shown to influence cell proliferation, differentiation and migration. They are also involved in filtration and tissue compartmentalization and serve as barriers to cancer cells.

All BMs contain members of four protein families: type IV collagen, nidogen/entactin, sulfated proteoglycans and laminin (reviewed by Sasaki et al., 2004). The particular protein isoforms present in a given BM are presumed to impart unique functional properties important for behavior of the adjacent cells and for organ development and function. Perhaps the best evidence for this is the fact that mutations in genes encoding BM proteins cause human disease, despite substitution by related isoforms in some cases. For example, Alport syndrome is a type IV collagen disease of kidney and inner ear (Kashtan, 2004); Knobloch syndrome is a collagen XVIII (heparan sulfate proteoglycan) disease affecting the eye (Suzuki et al., 2002); and Herlitz's junctional epidermolysis bullosa and congenital muscular dystrophy type 1A are laminin diseases of the skin and neuromuscular system, respectively (Burgeson and Christiano, 1997; Patton, 2000).

Laminins exist in BMs as α - β - γ heterotrimers. In mammals there are five α , four β and three γ chains that assemble nonrandomly to form at least 15 different heterotrimers [see Aumailley et al.

(Aumailley et al., 2005) for a new laminin nomenclature] (reviewed by Miner and Yurchenco, 2004). Evidence from zebrafish supports the existence of a fourth β chain (Parsons et al., 2002). Mutations in ten of the eleven known mouse laminin genes have been reported. These studies have shown that laminin is absolutely required for BM formation (Miner et al., 2004; Smyth et al., 1999) and that laminins play roles in diverse developmental and physiological processes (reviewed by Miner and Yurchenco, 2004; Yurchenco et al., 2004).

Recently, mutations in the laminin $\beta 2$ gene (*LAMB2*) were reported in a rare, lethal human disease called Pierson syndrome (Zenker et al., 2004a; Zenker et al., 2005). Pierson syndrome, also called microcoria-congenital nephrosis syndrome (OMIM 609049), is an autosomal recessive disease with congenital nephrotic syndrome/diffuse mesangial sclerosis, distinct ocular abnormalities including microcoria (small pupil), and impairment of vision and neurodevelopment (Zenker et al., 2004b). These features are consistent with the phenotype of mice lacking laminin $\beta 2$, which stop gaining weight at 1 week of age and die at ~3 weeks of age. *Lamb2*^{-/-} mice exhibit heavy proteinuria/congenital nephrotic syndrome with podocyte foot process effacement (Noakes et al., 1995b), aberrantly formed and functionally impaired neuromuscular junctions (Knight et al., 2003; Nishimune et al., 2004; Noakes et al., 1995a; Patton et al., 1998), and both structural and functional abnormalities in the retina (Libby et al., 1999). These phenotypes reflect the fact that laminin $\beta 2$ has been reported to be concentrated in the kidney glomerulus and at the skeletal neuromuscular junction (Hunter et al., 1989) and to be deposited in the retina (Libby et al., 2000; Libby et al., 1997).

Although the eye abnormalities would not be expected to impair the growth and longevity of *Lamb2*^{-/-} mice, the glomerular and neuromuscular defects probably contribute to the severity of the failure to thrive phenotype. However, it has been difficult to determine the extent to which each of these is involved. Moreover, laminin $\beta 2$ is expressed at other sites quite widely throughout the

¹Renal Division, Washington University School of Medicine, St Louis, MO 63110, USA. ²Department of Cell Biology and Physiology, Washington University School of Medicine, St Louis, MO 63110, USA. ³CROET, Oregon Health Sciences University, Portland, OR 97239, USA.

*Author for correspondence (e-mail: minerj@wustl.edu)

body (Sasaki et al., 2002), so there may exist defects in other tissues that are being masked by the severity of the kidney and muscle defects. To investigate these issues, which have relevance in terms of understanding both basic laminin biology and Pierson syndrome, we have used tissue-specific laminin $\beta 2$ transgenes to isolate the neuromuscular and kidney defects, rescuing each one individually and both together by mating the transgenes onto the *Lamb2*^{-/-} background. A similar approach was previously used to isolate skeletal muscle defects from those in peripheral nerve in *Lama2* mutant mice (Kuang et al., 1998). Our results suggest that the neuromuscular defect, rather than the kidney defect, is responsible for the severe overt phenotype. Furthermore, a requirement for laminin $\beta 2$ in tissues other than muscle and kidney to maintain normal viability could not be demonstrated.

MATERIALS AND METHODS

Construction of rat laminin $\beta 2$ transgenes

To construct the MCK-B2 transgene, the full-length rat laminin $\beta 2$ cDNA (Green et al., 1992) (a gift from Joshua R. Sanes, Harvard University, Cambridge, MA) was inserted between the 3.3 kb mouse muscle creatine kinase (MCK) enhancer/promoter and the SV40 large T-antigen transcription termination and polyadenylation signal sequences (Jaynes et al., 1988) (a gift from Jean Buskin and Stephen Hauschka, University of Washington, Seattle, WA). To construct the NEPH-B2 transgene, the rat $\beta 2$ cDNA plus SV40 3' processing signals from MCK-B2 were flanked with loxP sites and inserted downstream of the 4.2 kb mouse nephrin promoter (Eremina et al., 2002) (a gift from Susan Quaggin, University of Toronto, Toronto, Canada).

Production of laminin $\beta 2$ knockout and transgenic mice

Production of mice carrying the targeted *Lamb2* mutation (gift from Joshua R. Sanes) has been previously described (Noakes et al., 1995a). Briefly, the MC1neo cassette was inserted into the AgeI site in the second exon of mouse *Lamb2*. Antibodies to epitopes encoded by mRNA sequences 3' of this insertion did not stain homozygous mutants (Noakes et al., 1995b; Sasaki et al., 2002), indicating that the insertion generates a null mutation. Mice were genotyped by PCR of DNA extracted from tail clips using the following primer pairs: for the mutant allele (MC1neo-specific), 5'-CGAATTC-GAACACGCAGATGCAG-3' and 5'-CCGGGCGCCCCCTGCGCTGAC-AGC-3'; for the wild-type allele, 5'-TGACCCACTGTCTCAGTGCTG-3' and 5'-GAGTGTAGGATAGGTACCTTAG-3'.

To produce transgenic mice, the transgenes were digested and gel-purified away from plasmid vector sequences and then microinjected individually into the pronuclei of single-celled B6CBF2/J embryos by the Washington University Mouse Genetics Core. Founders and their transgenic offspring were identified by PCR of DNA extracted from tail clips using the following primers: for MCK-B2, 5'-CTGGCTAGTCACACCTGTAGG-3' (MCK forward) and 5'-CTGGATAGCAGCTTCCTCGAG-3' ($\beta 2$ reverse); for NEPH-B2, 5'-GAAGCAGCAGAATGAGTTCACAC-3' (nephrin forward) and 5'-ATACGAAGTTATTCGAAGTCGAG-3' (vector/loxP sequences between the nephrin promoter and the $\beta 2$ cDNA).

Antibodies, immunostaining and histology

Mouse mAbs D5 and D7 that recognize the rat laminin $\beta 2$ C-terminal coiled-coil domain (Hunter et al., 1989; Sanes et al., 1990) were gifts from Joshua R. Sanes and were also obtained from the Developmental Studies Hybridoma Bank (Iowa City, IA). Polyclonal antisera to the mouse laminin $\beta 2$ LF domain (formerly called domain IV) (Sasaki et al., 2002), which crossreact with rat $\beta 2$, were a gift from Takako Sasaki and the late Rupert Timpl (Max Planck Institute for Biochemistry, Martinsried, Germany). Rat mAb 5A2 to the mouse laminin $\beta 1$ LN domain (formerly VI) (Abrahamson et al., 1989; St John et al., 2001) was a gift from Dale Abrahamson (University of Kansas Medical Center, Kansas City, KS). Rabbit antiserum 8948 to the mouse laminin $\alpha 5$ LEb and L4b domains (formerly IIIb and IVa) has been described (Miner et al., 1997). Alexa 488- and Cy3-conjugated secondary antibodies were obtained from Molecular Probes (Eugene, OR) and Chemicon (Temecula, CA), respectively.

For immunostaining, fresh tissues were immersed in OCT and quick-frozen in 2-methylbutane cooled in a dry ice-ethanol bath. Frozen sections were cut (7 μ m) in a cryostat and air dried on gelatin-coated slides. Antibodies were diluted in PBS with 1% BSA, applied to sections for 1 hour, and rinsed in PBS. Secondary antibodies were then applied in a similar fashion. TRITC-conjugated α -bungarotoxin (Molecular Probes) was included to localize synaptic sites in skeletal muscle. After rinsing, the sections were mounted in 90% glycerol containing 0.1 \times PBS and 1 mg/ml *p*-phenylenediamine and viewed under epifluorescence with a Nikon Eclipse 800 compound microscope. Images were captured with a Spot 2 cooled color digital camera (Diagnostic Instruments, Sterling Heights, MI).

For conventional light microscopy, tissues were fixed in 10% buffered formalin, dehydrated through graded ethanols, embedded in paraffin, sectioned at 4 μ m and stained with periodic-acid-Schiff (PAS). For electron microscopy, tissues were fixed, embedded in plastic, sectioned and stained as previously described (Kikkawa et al., 2003; Noakes et al., 1995b).

Evans blue analysis

To assay the integrity of skeletal muscle fibers, Evans blue dye (Sigma, St Louis, MO) at 10 mg/ml in 0.9% NaCl was injected intraperitoneally at 10 μ l/g body weight. After 6 hours mice were perfused under anesthesia with 10 ml PBS and then 40 ml of 2% paraformaldehyde in PBS. The diaphragm with rib insertions was dissected out and post-fixed overnight with 3% paraformaldehyde and 1% glutaraldehyde in PBS at 4°C. The diaphragm was then detached from the ribs and photographed with a QImaging Micropublisher digital camera (QImaging, Burnaby, BC, Canada) attached to a stereomicroscope.

Urinalysis

Urine was collected from mice at various ages either by manual restraint, by caging on raised wire floors (Ancare, Bellmore, NY) for several hours or by bladder puncture under anesthesia at the time of sacrifice. Urine (1 μ l) was run on precast 4 to 20% SDS polyacrylamide gels (Invitrogen/Novex, Carlsbad, CA), and gels were stained with Coomassie Blue and destained by standard methods. For quantitation, urinary protein and creatinine concentrations were measured with a Cobas Mira Plus analyzer (Roche, Somerville, NJ).

RESULTS

Generation and characterization of laminin $\beta 2$ transgenic mice

We wished to isolate the muscle and kidney defects observed in *Lamb2*^{-/-} mice so that they could be studied independently of one another. The failure to thrive phenotype of *Lamb2*^{-/-} mice is so severe that indirect effects of the kidney and neuromuscular diseases on each other, and perhaps on other tissues, could not be ruled out. One approach to accomplish this would be to make cell type-specific knockouts using Cre/loxP technology. However, we chose to attempt to rescue selectively each defect individually using cell type-specific laminin $\beta 2$ transgenes expressed on the *Lamb2*^{-/-} background.

Muscle-specific $\beta 2$ transgene

The reported developmental defects in *Lamb2*^{-/-} muscles are restricted to the synapse. Consistent with this, laminin $\beta 2$ is concentrated in the synaptic region of the myofiber BM; it also accumulates at myotendinous junctions (MTJs) (Patton et al., 1997) and can be detected extrasynaptically with some antibodies (Hunter et al., 1989; Sasaki et al., 2002; Wewer et al., 1997). Previous studies have shown that $\beta 2$ is expressed by skeletal muscle in vivo (Moscoso et al., 1995) and is concentrated at synapse-like sites that form on cultured myotubes in vitro even in the absence of neurons (Martin et al., 1995). Together, these data suggest that skeletal muscle is capable of concentrating laminin $\beta 2$ at synaptic sites independent of motoneuron expression of $\beta 2$, should there be any. We therefore constructed a $\beta 2$ transgene (MCK-B2; Fig. 1A) that




Fig. 1. Structure of the transgenes. (A) The MCK-B2 transgene drives rat laminin $\beta 2$ expression from the mouse muscle creatine kinase (MCK) promoter, and transcription termination and polyadenylation signal sequences from SV40 (pA) ensure processing to mRNA. (B) The NEPH-B2 transgene drives $\beta 2$ expression from the mouse nephron promoter. The $\beta 2$ cDNA and SV40 sequences were flanked by loxP sites for future manipulations.

should be expressed at high levels in skeletal muscle, using the well-characterized mouse MCK enhancer/promoter. This element has also been shown to drive expression in cardiac muscle with ~100-fold less activity, but, importantly, it is not significantly active in kidney (Johnson et al., 1989). We chose to use the rat $\beta 2$ cDNA because of the availability of mouse mAbs that recognize rat but not mouse $\beta 2$ (Sanes et al., 1990). These mAbs facilitated specific detection of transgene-derived $\beta 2$.

Seven MCK-B2 transgenic founders were generated. Because mouse tail contains multiple tissue types, including some skeletal muscle, transgene expression was assayed by staining frozen sections of a tail biopsy from each founder with anti-rat $\beta 2$ monoclonal antibodies. Muscle synaptic sites were identified by co-staining with TRITC-conjugated α -bungarotoxin, which binds to acetylcholine receptors. Two of the seven founders expressed rat $\beta 2$, and it was concentrated at synapses. These two were mated to *Lamb2*^{+/-} mice to generate *Lamb2*^{+/-}; MCK-B2 lines.

Analysis of offspring showed that only one of the two lines deposited the transgene-derived $\beta 2$ consistently at all synapses, and this line was used for subsequent studies. An immunohistochemical survey of tissues was performed to determine whether expression was muscle specific. Rat $\beta 2$ was detected at skeletal muscle synapses (Fig. 2C,D), but not in extrasynaptic regions of the myofiber BM. This is in contrast to the endogenous mouse $\beta 2$, which is found in both synaptic and extrasynaptic regions (Fig. 2A) (Sasaki et al., 2002). Expression was also observed in cardiac muscle and in some visceral smooth muscle, but not in nerve, kidney, lung parenchyma, skin, liver, retina, intestinal mucosa or brain (Fig. 2E-H and data not shown). Mosaic expression was observed in the vascular smooth muscle of arteries (data not shown). Based on these results, we conclude that the MCK-B2 transgene behaves in an appropriate tissue-specific fashion and that the presumed expression of the transgene throughout the skeletal muscle fiber nevertheless leads to concentration of $\beta 2$ at synapses, as previously shown in vitro (Martin et al., 1995).

Podocyte-specific $\beta 2$ transgene

The known defects in *Lamb2*^{-/-} kidney are restricted to the glomerular filter, consistent with the fact that $\beta 2$ is highly concentrated in the glomerular BM (GBM) (Hunter et al., 1989). The GBM is synthesized by two cells: the podocytes that are present in the urinary space and lie on the outer aspect of the GBM, and the endothelial cells that line the glomerular capillaries on the inner aspect of the GBM (St John and Abrahamson, 2001). In order to restrict rat $\beta 2$ transgene expression to the glomerulus, we chose to




Fig. 2. Localization of endogenous and MCK-B2 transgene-derived laminin $\beta 2$. (A,B) In control skeletal muscle, endogenous mouse laminin $\beta 2$ (A) is concentrated at synapses (arrows) doubly labeled by α -bungarotoxin (B); $\beta 2$ is also found in extrasynaptic regions of muscle fibers (A). (C,D) In MCK-B2 transgenics, antibody specific for transgene-derived rat $\beta 2$ (C) labels only synapses in skeletal muscle (arrows), identified by α -bungarotoxin (D). (E-H) Transgene-derived rat laminin $\beta 2$ is also found in cardiac muscle BMs (E), in circular (cm) but not longitudinal (lm) smooth muscle or crypt (c) epithelial BMs of intestine (G), and weakly in large airway smooth muscle of lung (arrow in H) but not in alveolar (alv) BMs. No rat $\beta 2$ was detected in glomeruli (g) in kidney (F). Scale bars: 25 μ m in A-D; 100 μ m in E,H; 50 μ m in F,G.

use a podocyte-specific promoter element isolated from the *Nphs1* gene (Eremina et al., 2002), which encodes nephrin (Kestila et al., 1998), to make the NEPH-B2 transgene (Fig. 1B). For added flexibility in future experiments, the rat $\beta 2$ cDNA and the adjacent SV40 sequences were flanked by loxP sites so that transgene expression could be halted by Cre-mediated recombination.

Three NEPH-B2 transgenic founders were obtained, and each was mated to a *Lamb2*^{+/-} mouse to generate three independent lines. Transgene expression was assayed in offspring by immunostaining kidney sections for rat $\beta 2$, which was never detected in non-transgenic controls (Fig. 3A). All three transgenes were expressed, and rat $\beta 2$ was only detected in the GBM (Fig. 3B). However, deposition was segmental and weak in two of the three lines, so only the third was used for subsequent experiments. Rat $\beta 2$ deposition was not detected in any other tissues examined, including skeletal muscle, heart, intestine and lung (Fig. 3C,D; data not shown).

Tissue-specific transgenic rescue of *Lamb2*^{-/-} defects

Skeletal muscle rescue

To determine whether muscle-derived laminin $\beta 2$ was sufficient to rescue the *Lamb2*^{-/-} neuromuscular junction differentiation defects, and to attempt to isolate the glomerular filtration defect, *Lamb2*^{+/-} mice were crossed with *Lamb2*^{+/-}; MCK-B2 mice to generate *Lamb2*^{-/-}; MCK-B2 mice. *Lamb2*^{-/-}; MCK-B2 mice were significantly more healthy than *Lamb2*^{-/-} mice and were usually indistinguishable from littermate controls with respect to overall appearance and body weight during the pre-weaning period (Fig. 4A). However, they routinely died at 1 month of age, only ~10 days later than *Lamb2*^{-/-} mice. SDS-PAGE analysis of urine showed massive proteinuria before and after weaning, with albumin being the major urinary protein (Fig. 4B; data not shown). Quantitation of urinary protein to creatinine ratios showed that proteinuria in *Lamb2*^{-/-}; MCK-B2 mice was comparable with that observed in *Lamb2*^{-/-} mice. Consistent with the heavy proteinuria, *Lamb2*^{-/-}; MCK-B2 mice were edematous near the time of death.

Immunohistochemical analyses showed that in skeletal muscle, rat $\beta 2$ was concentrated at synaptic sites in *Lamb2*^{-/-}; MCK-B2 mice (Fig. 5). Interestingly, as discussed in detail in the Discussion, even with the more sensitive polyclonal antibody, little $\beta 2$ was detectable along the extra-synaptic regions of the myofiber. (One exception was

the MTJ, as shown below.) Expression was also detected in cardiac muscle but not in kidney or in other non-muscle tissues, consistent with the data in Fig. 2.

We have previously shown that loss of $\beta 2$ from synapses in *Lamb2*^{-/-} muscle leads both to loss of laminin $\alpha 5$, the partner of laminin $\beta 2$ in the synaptic laminin $\alpha 5\beta 2\gamma 1$ (laminin-11 or Lm-521), and to increased synaptic $\beta 1$ (Patton et al., 1997), which presumably compensates for the absence of $\beta 2$. Here, restoration of $\beta 2$ to the synaptic cleft in *Lamb2*^{-/-}; MCK-B2 mice led to the reappearance of $\alpha 5$ and the disappearance of $\beta 1$ (Fig. 5C-F). Not only was the molecular composition of the synaptic BM normalized, but the endplate also acquired the normal pretzel-like shape (Fig. 5B) that *Lamb2*^{-/-} synapses lack (Noakes et al., 1995a). Ultrastructural analyses further confirmed the rescue of synaptic organization: the muscle endplate established junctional folds, and Schwann cell processes did not aberrantly extend into the synaptic cleft (Fig. 6A-C). We conclude that muscle-derived $\beta 2$ is deposited into the synaptic cleft BM and is sufficient to rescue synaptic structural and compositional defects in the *Lamb2* mutant. The overall improvement in health of the animal suggests that synaptic function is also improved.

As mentioned previously, laminin $\beta 2$ is also normally concentrated at MTJs, but developmental defects in *Lamb2*^{-/-} MTJs have not previously been reported. Injection of Evans blue, a dye that accumulates only in damaged and regenerating skeletal and cardiac




Fig. 3. NEPH-B2 transgene-derived laminin $\beta 2$ accumulates specifically in the GBM. (A,B) Antibody specific for transgene-derived rat $\beta 2$ does not stain kidney glomeruli (g) from a control mouse (A) but stains GBM in kidney from NEPH-B2 transgenic mice (B). (C,D) NEPH-B2 transgene-derived $\beta 2$ is not deposited at skeletal muscle synapses (C) identified by double staining with α -bungarotoxin (D). Scale bar: 50 μ m in A,B; 20 μ m in C,D.




Fig. 4. Analysis of growth rates and urinary protein levels.

(A) Growth curves (weight versus age) of control mice, *Lamb2*^{-/-} mice and *Lamb2*^{-/-} mice carrying transgenes. *Lamb2*^{-/-} and *Lamb2*^{-/-}; NEPH-B2 mice fail to surpass a weight of ~4 g and die at 3-4 weeks of age. By contrast, *Lamb2*^{-/-}; MCK-B2 mice grow at a rate similar to controls but die at 1 month of age. *Lamb2*^{-/-}; MCK-B2; NEPH-B2 doubly transgenic mice exhibit normal weight gain and a long life. (B) Proteinuria in *Lamb2*^{-/-}; MCK-B2 mice. Urine (1 μ l) was analyzed by SDS-PAGE and stained with Coomassie Blue. M, markers; the pink band is albumin. Lanes 1, 5 and 6: urine from *Lamb2*^{+/-}; MCK-B2 mice. Lanes 2, 4 and 7: urine from *Lamb2*^{-/-}; MCK-B2 mice. Lane 3 was empty.

muscle fibers (Straub et al., 1997), into *Lamb2*^{-/-} mice resulted in labeling of muscle fibers in the diaphragm, but primarily at the ends, near MTJs (Fig. 7A,B). (This pattern contrasts with the labeling observed in typical dystrophic muscle, which occurs along the entire length of muscle fibers.) Furthermore, transmission electron microscopy showed that the BM associated with the MTJ was somewhat discontinuous and less compact compared with control, and the folding at the end of mutant muscle fibers exhibited reduced complexity (Fig. 6E,F). Together, these data suggest that in the absence of laminin β 2, MTJs are structurally and functionally defective.

In *Lamb2*^{-/-}; MCK-B2 mice, β 2 was detectable at most if not all MTJs (Fig. 7F), and this correlated with improved ultrastructure in some fibers (Fig. 6G). But surprisingly, muscle fibers in *Lamb2*^{-/-}; MCK-B2 mice were still labeled by Evans blue near MTJs (Fig. 7C). A possible explanation stems from our analysis of *Lamb2*^{+/-}; MCK-B2 MTJs, which should contain both endogenous mouse and transgene-derived rat β 2. However, double staining for total and for transgene-derived rat β 2 revealed that many MTJs do not contain rat β 2, though they contain the endogenous mouse β 2 (Fig. 7G,H). This shows that transgene-derived protein accumulates at MTJs inefficiently compared to endogenous protein. It then follows that transgene-derived β 2 should also accumulate inefficiently at MTJs in *Lamb2*^{-/-}; MCK-B2 mice (though it does accumulate, as shown in Fig. 7F), which could lead to a mild injury to the developing muscle and the observed Evans blue uptake in the highly active diaphragm.




Fig. 5. Restoration of proper synaptic architecture and BM composition in skeletal muscle from *Lamb2*^{-/-}; MCK-B2 mice. (A,B) Colocalization of rat laminin β 2 (A) with α -bungarotoxin (B) in a highly ramified skeletal muscle synapse. (C,D) Restoration of laminin α 5 to synaptic BMs (C) identified by α -bungarotoxin (D). (E,F) Laminin β 1 (E, green in F) is not associated with the α -bungarotoxin-positive synaptic clefts (red in the merged image in F). Scale bar: 20 μ m for A-F.

Kidney rescue

To determine whether podocyte-derived laminin β 2 is sufficient to restore the glomerular filtration barrier, and to attempt to isolate the neuromuscular defects, *Lamb2*^{+/-}; NEPH-B2 mice were crossed with *Lamb2*^{-/-} mice to generate *Lamb2*^{-/-}; NEPH-B2 mice. These mice were overtly indistinguishable from and had growth curves similar to *Lamb2*^{-/-} mice (Fig. 4A), and they died at 3–4 weeks of age, suggesting little improvement in overall health. However, immunohistological analysis revealed efficient deposition of rat β 2 into the GBM (Fig. 8), and urinalysis revealed that there was no proteinuria in *Lamb2*^{-/-}; NEPH-B2 mice (data not shown). The abrogation of proteinuria led to no obvious improvement in synaptic architecture in the absence of synaptic β 2 (Fig. 6D), demonstrating for the first time that synaptic defects in *Lamb2*^{-/-} mice are not secondary to ill health caused by proteinuria. Based on these results, we conclude that the severe phenotype in *Lamb2*^{-/-} mice stems primarily from the neuromuscular junction defects.

We have previously shown that there is a laminin β 1 to β 2 developmental transition in the forming GBM (Miner and Sanes, 1994). In *Lamb2*^{-/-} mice, β 1 remains in the GBM rather than being eliminated, thus serving a structural role to maintain GBM integrity, but nevertheless failing to maintain the glomerular barrier to protein (Noakes et al., 1995b). Here, restoration of podocyte-derived β 2 to the GBM was accompanied by proper elimination of β 1 as glomeruli matured, though it was still detectable in the mesangial matrix (Fig. 8). Ultrastructural analysis showed normal podocyte foot process architecture in *Lamb2*^{-/-}; NEPH-B2 glomeruli at all stages, even at a time near death (Fig. 6H,K; data not shown). By contrast, analysis of *Lamb2*^{-/-} and *Lamb2*^{-/-}; MCK-B2 glomeruli revealed widespread foot process effacement (Fig. 6H–J), consistent with the heavy proteinuria (Fig. 4B).

Combined transgenic rescue of muscle and kidney defects

We next generated *Lamb2*^{-/-}; MCK-B2; NEPH-B2 mice through appropriate crosses. Except for occasional mild proteinuria, these mice have manifested no obvious defects and can live for well over 1 year, some to 18 months. Both males and females have exhibited normal fertility and are overtly indistinguishable from control littermates. Light microscopic analysis of PAS-stained paraffin sections revealed no significant pathology in either skeletal muscle or kidney in older mice (Fig. 9), and ultrastructural analysis of glomeruli and neuromuscular junctions showed no significant abnormalities (data not shown). Interestingly, Evans blue only occasionally labeled the ends of muscle fibers in the diaphragms of older doubly rescued mice (Fig. 7D and data not shown), and all MTJs contained β 2 (Fig. 7I–L), suggesting that subsequent to any initial injury at developmental stages, as in Fig. 7C, MTJs are apparently repaired. Furthermore, no histopathology was observed in other tissues reported to be rich in β 2, including lung, retina, pancreas or gut (data not shown). Based on these results, a requirement for β 2 in BMs other than those associated with muscle and the kidney glomerulus can not be demonstrated, at least in the context of the controlled environment of a mouse cage.

DISCUSSION

Accumulating evidence shows that laminins play crucial roles in the development and function of many organs, as well as in such fundamental developmental processes as gastrulation, notochord formation and neural tube closure (Miner and Yurchenco, 2004). The growth of the laminin family during the evolution of multicellular organisms has allowed a segregation of laminins into




Fig. 6. Ultrastructural analysis of neuromuscular junctions (NMJ), myotendinous junctions (MTJ) and glomerular filtration barriers. (A–D) A control synapse (A) shows a Schwann cell (s) capping the vesicle-rich nerve terminal (nt) adjacent to the muscle (m) endplate containing numerous junctional folds (jf). In the *Lamb2*^{-/-} synapse (B), junctional folds are absent and the Schwann cell extends processes (arrow) between the nerve terminal and the muscle. Synaptic deposition of laminin β 2 in *Lamb2*^{-/-}; MCK-B2 mice restores synaptic architecture to normal (C). In *Lamb2*^{-/-}; NEPH-B2 mice, glomerular deposition of β 2 and prevention of proteinuria has no restorative effect on the synapse (D). (E–G) MTJ from a control (E) exhibits numerous infoldings of the muscle fiber (m) with continuous BMs. In the *Lamb2*^{-/-} MTJ (F), infoldings are less complex, and the BMs (arrows) appear fuzzy. MCK-B2 transgene-derived β 2 restores much of the normal MTJ architecture (G). (H–K) Glomerular capillary segment from a control (H) shows the interdigitated podocyte foot processes (fp) adjacent to the GBM. Effaced foot processes (efp) are evident in the *Lamb2*^{-/-} (I) and *Lamb2*^{-/-}; MCK-B2 (J) mice, which are proteinuric. Deposition of rat β 2 into the GBM in *Lamb2*^{-/-}; NEPH-B2 mice prevents proteinuria and foot process effacement (K). Scale bars in D and K are 1 μ m for A–D and H–K, respectively; scale bar in G is 2 μ m for E–G.




Fig. 7. Functional and compositional analyses of MTJs. (A–D) Evans blue analysis reveals normal MTJ integrity in a control mouse diaphragm (A), but evidence of damage is observed in *Lamb2*^{-/-} (B) and *Lamb2*^{-/-}; MCK-B2 (C) mice at 3 weeks of age. A diaphragm from an older adult *Lamb2*^{-/-}; MCK-B2; NEPH-B2 mouse shows no damage (D), suggesting eventual repair of MTJs. (E, F) Double staining for laminin β 2 (green) and laminin α 2 (red) in intercostal muscles reveals concentration of β 2 at MTJs in both control (E) and *Lamb2*^{-/-}; MCK-B2 (F) mice. (G, H) Double staining for mouse plus rat β 2 (G) and rat β 2 only (H) in a *Lamb2*^{-/-}; MCK-B2 mouse shows that many MTJs contain little if any transgene-derived protein. (I–L) Double staining for total laminin β 2 (green) and α 2 (red) in intercostal muscles from aged control (I, J) and *Lamb2*^{-/-}; MCK-B2; NEPH-B2 (K, L) mice reveals efficient accumulation of β 2 at MTJs. Transgene-derived β 2 is missing from extra-junctional BMs in rescued mutant muscle fibers (F, K). Scale bars: in D, 1 mm for A–D; in H, 50 μ m for A–I, K; in L, 20 μ m for J, L.




Fig. 8. Analysis of laminin β chain composition in glomeruli. (A,B) In *Lamb2*^{+/+}; NEPH-B2 mice, the GBM contains rat laminin β 2 (A), and laminin β 1 is restricted to the mesangial matrix (B). (C,D) In *Lamb2*^{-/-} mice, no β 2 is present in the GBM (C); instead, β 1 is present (arrows in D). (E,F) In *Lamb2*^{-/-}; NEPH-B2 mice, rat β 2 is deposited into the GBM (E), and β 1 is restricted to the mesangial matrix (F) as in controls. Scale bar: 25 μ m.

two distinct groups in vertebrates: one group containing laminins absolutely required during embryogenesis for basic developmental processes, and the second containing laminins with more restricted, specialized functions in postnatal animals.

Here, we have focused on the laminin β 2 chain, which falls squarely into the latter group. Although laminin β 2 has no obvious function during development in utero, and *Lamb2*^{-/-} pups are indistinguishable from control littermates during the first postnatal week, homozygotes die at ~3 weeks of age with severe defects in both the glomerular filter and the neuromuscular junction (Noakes et al., 1995a; Noakes et al., 1995b). Whether there might be defects in other tissues (besides retina) (Libby et al., 1999), and how the kidney and muscle defects each contribute to the lethal failure to thrive phenotype, have been important unanswered questions. The recent finding of mutations in *LAMB2* associated with Pierson syndrome (Zenker et al., 2004a; Zenker et al., 2005) underscores the importance of these issues with regard to human development and disease.

To investigate whether the kidney or the synapse defect is most detrimental to the health of the animals, we used tissue-specific laminin β 2 transgenes to rescue each defect individually. We have clearly shown that the defects in synaptic development and maturation are much more devastating: rescuing the GBM defects with the podocyte-specific β 2 transgene (NEPH-B2) did not improve the overt phenotype of the *Lamb2* mutant, whereas rescuing the structure and presumably the function of the neuromuscular junction with the muscle-specific β 2 transgene




Fig. 9. Histological analysis of skeletal muscle and kidney. Aged control (A,C,E) and *Lamb2*^{-/-}; MCK-B2; NEPH-B2 (B,D,F) mice. Paraffin sections were stained with PAS. No obvious pathology was observed in either skeletal muscle (A,B) or kidney (C,D; glomeruli at high power in E,F) from control or transgene-rescued mutant mice. Scale bar in B, 500 μ m; in D, 200 μ m; in F, 50 μ m.

(MCK-B2) greatly improved weight gain and extended lifespan by ~50%. The latter mice must have died from nephrotic syndrome, because preventing it through simple addition of the NEPH-B2 transgene allowed for a very long life (well over 1 year) and normal fertility in *Lamb2*^{-/-}; MCK-B2; NEPH-B2 mice. Furthermore, we can conclude from this result that for normal longevity of caged mice, laminin β 2 is only required in muscle and glomerular BMs, the only sites where we could detect β 2 in *Lamb2*^{-/-}; MCK-B2; NEPH-B2 mice. Such an important conclusion would not have been possible had we chosen to use the more conventional Cre/loxP conditional knockout approach to mutate *Lamb2* specifically in skeletal muscle or podocytes, because all tissues not expressing Cre would contain their normal complement of β 2.

Because the MCK regulatory element is active in both skeletal and cardiac muscle and, to a much lesser extent, in smooth muscle (Jaynes et al., 1988; Johnson et al., 1989), we cannot be absolutely certain that the basis for improvement in the health of *Lamb2*^{-/-}; MCK-B2 mice is solely due to restored synaptic architecture and function. But the fact that *Lamb2*^{-/-} hearts exhibit no obvious morphological or histopathological defects, such as ventricular dilation or cardiomyocyte necrosis or fibrosis (J.H.M., B.L.P. and G.J., unpublished), suggests that the improved health of *Lamb2*^{-/-}; MCK-B2 mice is not due to transgene expression in the heart. Moreover, that cardiac defects are not generally associated with Pierson syndrome (Zenker et al., 2004b) is also consistent with the lack of a crucial role for laminin β 2 in the heart.

So why do defects in synaptic structure and function kill *Lamb2*^{-/-} mice? The mice usually die at ~21 days of age, which is also the time of weaning. Together with the highly significant 50% decrease in mean quantal content at mutant nerve terminals (Knight et al., 2003), the most likely explanation for death is that the mice are simply unable to use their muscles properly to obtain nutrition. Before weaning, this involves suckling for many hours each day, in addition to competing with littermates for access to teats; after weaning, it involves obtaining and chewing solid food and reaching for water. Consistent with this explanation, we have found that hand feeding *Lamb2*^{-/-} mice can extend their life to up to 40 days of age, though they remain very small and weak. A lack of proper nutrition is fully consistent with the observed failure to thrive phenotype.

Although laminin $\beta 2$ is concentrated at skeletal muscle synapses, it can normally also be detected extrasynaptically all along the muscle fiber with certain antibodies (Sasaki et al., 2002; Wewer et al., 1997), suggesting that the muscle deposits $\beta 2$ along its entire length. Here, however, little MCK-B2 transgene-derived $\beta 2$ was detected in the muscle fiber BM, other than at synapses and MTJs. Because there is no reason to suspect that the MCK regulatory element is not active in nuclei throughout the entire muscle fiber, these data suggest that skeletal muscle fibers are programmed to deposit $\beta 2$ only in synaptic and MTJ BMs. This was predicted in part by in vitro data demonstrating that the laminin $\beta 2$ protein contains an inherent signal that targets it to synapse-like sites on cultured myotubes (Martin et al., 1995). Another cell type – perhaps the interstitial fibroblast – is likely to be responsible for deposition of laminin $\beta 2$ along the extra-junctional regions of the muscle fiber.

During kidney glomerular development, distinct BMs synthesized by the epithelial podocytes and the invading endothelium fuse to form the immature GBM (Abrahamson and Perry, 1986). The laminin component of the maturing GBM continues to be synthesized by both the podocytes and the endothelial cells (St John and Abrahamson, 2001). Our approach to restore laminin $\beta 2$ to the mutant GBM by expressing it exclusively in podocytes via the nephrin promoter was successful in several respects, including localization to the GBM, restoration of the glomerular barrier to protein and restriction of laminin $\beta 1$ to the mesangium. This indicates that though GBM laminin $\beta 2$ is normally synthesized by both podocytes and endothelial cells, expression in podocytes is sufficient for normal GBM structure and function.

Our results have important implications for Pierson syndrome, which is caused by mutations in human *LAMB2* (Zenker et al., 2004a; Zenker et al., 2005). Individuals with this disease present with congenital nephrotic syndrome, diffuse mesangial sclerosis and microcoria (fixed narrowing of the pupils) associated with absent dilator pupillae muscles in the iris. Other eye abnormalities include an almost absent ciliary body, an enlarged cornea, an abnormal lens shape, maldevelopment of the choroid and arrested retinal development. No obvious structural abnormalities of the brain have been found, but muscular hypotonia and abnormal movements have been reported (Zenker et al., 2004b). Affected individuals usually die within weeks of birth from kidney failure, but some have lived for over 2 years. The kidney and retinal defects seem to correlate quite well with defects in the *Lamb2* mutant mouse, and the muscular hypotonia may stem from similar defects in development and function of the neuromuscular junction. However, cornea, lens and pupillary defects have not been found in the mouse.

Because of the availability of renal replacement therapy, through either dialysis or transplantation, the congenital nephrosis is the most treatable aspect of Pierson syndrome. However, the results of our transgenic rescue studies show that ameliorating the nephrotic

syndrome on its own is not significantly beneficial in extending the life of the *Lamb2*^{-/-} mouse. This calls into question whether renal replacement therapy alone is warranted in individuals with Pierson syndrome. Indeed, one individual who received chronic dialysis treatment and lived for 1.8 years exhibited significant neurological and developmental deficits including severe hypotonia, psychomotor delay, and blindness (Zenker et al., 2004a). Recently, a missense mutation in *LAMB2* was reported in a patient exhibiting congenital nephrotic syndrome but not the other features of Pierson syndrome (Hasselbacher et al., 2005), demonstrating that there is heterogeneity in the severity of disease resulting from *LAMB2* mutations in humans. As more individuals with *LAMB2* mutations are discovered and genotype-phenotype correlations are discerned, a better understanding of the neurological and muscular defects will hopefully emerge and lead to the development of extra-renal treatment paradigms.

We are grateful to Joshua R. Sanes for advice and for laminin $\beta 2$ plasmid, antibodies and mutant mice; to Jean Buskin, Stephen Hauschka and Susan Quaggin for plasmids; to Dale Abrahamson, Takako Sasaki and the late Rupert Timpl for antibodies; to Cong Li, Jennifer Richardson, Dan Martin and Marilyn Levy for technical assistance; and to the Mouse Genetics Core for production and care of mice. This work was supported by an Established Investigator Award from the American Heart Association and grants from the NIH (R01DK064687 and R01GM060432) to J.H.M., by a grant from the NIH (R01NS040759) to B.L.P., and by a Research Grant from the National Kidney Foundation of Eastern Missouri and Metro East to G.J.

References

- Abrahamson, D. R. and Perry, E. W. (1986). Evidence for splicing new basement membrane into old during glomerular development in newborn rat kidneys. *J. Cell Biol.* **103**, 2489-2498.
- Abrahamson, D. R., Irwin, M. H., St John, P. L., Perry, E. W., Accavitti, M. A., Heck, L. W. and Couchman, J. R. (1989). Selective immunoreactivities of kidney basement membranes to monoclonal antibodies against laminin: localization of the end of the long arm and the short arms to discrete microdomains. *J. Cell Biol.* **109**, 3477-3491.
- Aumailley, M., Bruckner-Tuderman, L., Carter, W. G., Deutzmann, R., Edgar, D., Ekblom, P., Engel, J., Engvall, E., Hohenester, E., Jones, J. C. R. et al. (2005). A simplified laminin nomenclature. *Matrix Biol.* **24**, 326-332.
- Burgeson, R. E. and Christiano, A. M. (1997). The dermal-epidermal junction. *Curr. Opin. Cell Biol.* **9**, 651-658.
- Eremina, V., Wong, M. A., Cui, S., Schwartz, L. and Quaggin, S. E. (2002). Glomerular-specific gene excision in vivo. *J. Am. Soc. Nephrol.* **13**, 788-793.
- Green, T. L., Hunter, D. D., Chan, W., Merlie, J. P. and Sanes, J. R. (1992). Synthesis and assembly of the synaptic cleft protein S-laminin by cultured cells. *J. Biol. Chem.* **267**, 2014-2022.
- Hasselbacher, K., Wiggins, R., Mucha, B., Hinkes, B., Pohl, M., Zenker, M., Ozaltin, F., Bakkaloglu, A., Hagan, D. and Hildebrandt, F. (2005). Recessive mutations in *LAMB2* as cause of congenital nephrotic syndrome (CNS). *J. Am. Soc. Nephrol.* **16**, 92A.
- Hunter, D. D., Shah, V., Merlie, J. P. and Sanes, J. R. (1989). A laminin-like adhesive protein concentrated in the synaptic cleft of the neuromuscular junction. *Nature* **338**, 229-234.
- Jaynes, J. B., Johnson, J. E., Buskin, J. N., Gartside, C. L. and Hauschka, S. D. (1988). The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer. *Mol. Cell. Biol.* **8**, 62-70.
- Johnson, J. E., Wold, B. J. and Hauschka, S. D. (1989). Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice. *Mol. Cell. Biol.* **9**, 3393-3399.
- Kashtan, C. E. (2004). Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy. *Curr. Opin. Pediatr.* **16**, 177-181.
- Kestila, M., Lenkkeri, U., Mannikko, M., Lamerdin, J., McCready, P., Putaala, H., Ruotsalainen, V., Morita, T., Nissinen, M., Herva, R. et al. (1998). Positionally cloned gene for a novel glomerular protein – nephrin – is mutated in congenital nephrotic syndrome. *Mol. Cell* **1**, 575-582.
- Kikkawa, Y., Virtanen, I. and Miner, J. H. (2003). Mesangial cells organize the glomerular capillaries by adhering to the G domain of laminin alpha5 in the glomerular basement membrane. *J. Cell Biol.* **161**, 187-196.
- Knight, D., Tolley, L. K., Kim, D. K., Lavidis, N. A. and Noakes, P. G. (2003). Functional analysis of neurotransmission at beta2-laminin deficient terminals. *J. Physiol.* **546**, 789-800.
- Kuang, W., Xu, H., Vachon, P. H., Liu, L., Loebel, F., Wewer, U. M. and

- Engvall, E. (1998). Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. *J. Clin. Invest.* **102**, 844-852.
- Libby, R. T., Xu, Y., Selfors, L. M., Brunken, W. J. and Hunter, D. D. (1997). Identification of the cellular source of laminin beta2 in adult and developing vertebrate retinae. *J. Comp. Neurol.* **389**, 655-667.
- Libby, R. T., Lavalley, C. R., Balkema, G. W., Brunken, W. J. and Hunter, D. D. (1999). Disruption of laminin beta2 chain production causes alterations in morphology and function in the CNS. *J. Neurosci.* **19**, 9399-9411.
- Libby, R. T., Champlaud, M. F., Claudepierre, T., Xu, Y., Gibbons, E. P., Koch, M., Burgeson, R. E., Hunter, D. D. and Brunken, W. J. (2000). Laminin expression in adult and developing retinae: evidence of two novel CNS laminins. *J. Neurosci.* **20**, 6517-6528.
- Martin, P. T., Ettinger, A. J. and Sanes, J. R. (1995). A synaptic localization domain in the synaptic cleft protein, s-laminin/laminin β 2. *Science* **269**, 413-416.
- Miner, J. H. and Sanes, J. R. (1994). Collagen IV α 3, α 4, and α 5 chains in rodent basal laminae: Sequence, distribution, association with laminins, and developmental switches. *J. Cell Biol.* **127**, 879-891.
- Miner, J. H. and Yurchenco, P. D. (2004). Laminin functions in tissue morphogenesis. *Annu. Rev. Cell Dev. Biol.* **20**, 255-284.
- Miner, J. H., Patton, B. L., Lentz, S. I., Gilbert, D. J., Snider, W. D., Jenkins, N. A., Copeland, N. G. and Sanes, J. R. (1997). The laminin alpha chains: expression, developmental transitions, and chromosomal locations of alpha1-5, identification of heterotrimeric laminins 8-11, and cloning of a novel alpha3 isoform. *J. Cell Biol.* **137**, 685-701.
- Miner, J. H., Li, C., Mudd, J. L., Go, G. and Sutherland, A. E. (2004). Compositional and structural requirements for laminin and basement membranes during mouse embryo implantation and gastrulation. *Development* **131**, 2247-2256.
- Moscoso, L. M., Merlie, J. P. and Sanes, J. R. (1995). N-CAM, 43K-rapsyn, and S-laminin mRNAs are concentrated at synaptic sites in muscle fibers. *Mol. Cell Neurosci.* **6**, 80-89.
- Nishimune, H., Sanes, J. R. and Carlson, S. S. (2004). A synaptic laminin-calcium channel interaction organizes active zones in motor nerve terminals. *Nature* **432**, 580-587.
- Noakes, P. G., Gautam, M., Mudd, J., Sanes, J. R. and Merlie, J. P. (1995a). Aberrant differentiation of neuromuscular junctions in mice lacking s-laminin/laminin β 2. *Nature* **374**, 258-262.
- Noakes, P. G., Miner, J. H., Gautam, M., Cunningham, J. M., Sanes, J. R. and Merlie, J. P. (1995b). The renal glomerulus of mice lacking s-laminin/laminin β 2: nephrosis despite molecular compensation by laminin β 1. *Nat. Genet.* **10**, 400-406.
- Parsons, M. J., Pollard, S. M., Saude, L., Feldman, B., Coutinho, P., Hirst, E. M. A. and Stemple, D. L. (2002). Zebrafish mutants identify an essential role for laminins in notochord formation. *Development* **129**, 3137-3146.
- Patton, B. L. (2000). Laminins of the neuromuscular system. *Microsc. Res. Tech.* **51**, 247-261.
- Patton, B. L., Miner, J. H., Chiu, A. Y. and Sanes, J. R. (1997). Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. *J. Cell Biol.* **139**, 1507-1521.
- Patton, B. L., Chiu, A. Y. and Sanes, J. R. (1998). Synaptic laminin prevents glial entry into the synaptic cleft. *Nature* **393**, 698-701.
- Sanes, J. R., Engvall, E., Butkowski, R. and Hunter, D. D. (1990). Molecular heterogeneity of basal laminae: Isoforms of laminin and collagen IV at the neuromuscular junction and elsewhere. *J. Cell Biol.* **111**, 1685-1699.
- Sasaki, T., Mann, K., Miner, J. H., Miosge, N. and Timpl, R. (2002). Domain IV of mouse laminin β 1 and β 2 chains: structure, glycosaminoglycan modification and immunochemical analysis of tissue contents. *Eur. J. Biochem.* **269**, 431-442.
- Sasaki, T., Fassler, R. and Hohenester, E. (2004). Laminin: the crux of basement membrane assembly. *J. Cell Biol.* **164**, 959-963.
- Smyth, N., Vatansever, H. S., Murray, P., Meyer, M., Frie, C., Paulsson, M. and Edgar, D. (1999). Absence of basement membranes after targeting the LAMC1 gene results in embryonic lethality due to failure of endoderm differentiation. *J. Cell Biol.* **144**, 151-160.
- St John, P. L. and Abrahamson, D. R. (2001). Glomerular endothelial cells and podocytes jointly synthesize laminin-1 and -11 chains. *Kidney Int.* **60**, 1037-1046.
- St John, P. L., Wang, R., Yin, Y., Miner, J. H., Robert, B. and Abrahamson, D. R. (2001). Glomerular laminin isoform transitions: errors in metanephric culture are corrected by grafting. *Am. J. Physiol. Renal Physiol.* **280**, F695-F705.
- Straub, V., Rafael, J. A., Chamberlain, J. S. and Campbell, K. P. (1997). Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. *J. Cell Biol.* **139**, 375-385.
- Suzuki, O. T., Sertie, A. L., Der Kaloustian, V. M., Kok, F., Carpenter, M., Murray, J., Czeizel, A. E., Kliemann, S. E., Rosemberg, S., Monteiro, M. et al. (2002). Molecular analysis of collagen XVIII reveals novel mutations, presence of a third isoform, and possible genetic heterogeneity in Knobloch syndrome. *Am. J. Hum. Genet.* **71**, 1320-1329.
- Wewer, U. M., Thornell, L. E., Loechel, F., Zhang, X., Durkin, M. E., Amano, S., Burgeson, R. E., Engvall, E., Albrechtsen, R. and Virtanen, I. (1997). Extrasynaptic location of laminin beta 2 chain in developing and adult human skeletal muscle. *Am. J. Pathol.* **151**, 621-631.
- Yurchenco, P. D., Amenta, P. S. and Patton, B. L. (2004). Basement membrane assembly, stability and activities observed through a developmental lens. *Matrix Biol.* **22**, 521-538.
- Zenker, M., Aigner, T., Wendler, O., Tralau, T., Muntefering, H., Fenski, R., Pitz, S., Schumacher, V., Royer-Pokora, B., Wuhl, E. et al. (2004a). Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. *Hum. Mol. Genet.* **13**, 2625-2632.
- Zenker, M., Tralau, T., Lennert, T., Pitz, S., Mark, K., Madlon, H., Dotsch, J., Reis, A., Muntefering, H. and Neumann, L. M. (2004b). Congenital nephrosis, mesangial sclerosis, and distinct eye abnormalities with microcoria: an autosomal recessive syndrome. *Am. J. Med. Genet. A* **130**, 138-145.
- Zenker, M., Pierson, M., Jonveaux, P. and Reis, A. (2005). Demonstration of two novel LAMB2 mutations in the original Pierson syndrome family reported 42 years ago. *Am. J. Med. Genet. A* **138**, 73-74.